4-新戊酰基氨基烟酸 | 125867-31-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-新戊酰基氨基烟酸
• 中文别名: 4-(2,2,2-三甲基乙酰氨基)烟酸
• 英文名称: 4-pivaloylaminopyridine-3-carboxylic acid
• 英文别名: 4-(tert-butylcarbonylamino)nicotinic acid；3-(2,2-dimethyl-propionylamino)-pyridine-2-carboxylic acid；4-(2,2-Dimethylpropanamido)pyridine-3-carboxylic acid；4-(2,2-dimethylpropanoylamino)pyridine-3-carboxylic acid
• CAS: 125867-31-4
• 化学式: C₁₁H₁₄N₂O₃
• mdl: MFCD03407344
• 分子量: 222.244
• InChiKey: UHGXHDOYHCDENE-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，没有已知危险反应。请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

SDS

Name:	4-[(2 2-Dimethylpropanoyl)amino]nicotinic acid 97% Material Safety Data Sheet
Synonym:
CAS:	125867-31-4

Section 1 - Chemical Product MSDS Name:4-[(2 2-Dimethylpropanoyl)amino]nicotinic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
125867-31-4	4-[(2,2-Dimethylpropanoyl)amino]nicoti	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 125867-31-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 246 - 250 deg C(decom)
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H14N2O3
Molecular Weight: 222.24

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 125867-31-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-[(2,2-Dimethylpropanoyl)amino]nicotinic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 125867-31-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 125867-31-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 125867-31-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：新戊酰基氨基烟酸是一种有机中间体，已有报道称它可以用于制备抗菌药物。

反应信息

• 作为反应物：
  描述：

  4-新戊酰基氨基烟酸 在 2,2,6,6-四甲基哌啶 、 正丁基锂 、 氨 、 乙酸酐 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 28.0h， 生成 2-(叔丁基)-8-碘吡啶并[4,3-d]嘧啶-4(3h)-酮
  参考文献：
  名称：

  通过金属化嘧啶嘧啶-4（3 H）-的吡啶部分进行的第一次官能化。二嗪。第36章

  摘要：

  从邻氨基吡啶羧酸开始，描述了导致各种吡啶并嘧啶-4（3H）-一个的一般合成路线。已经研究了吡啶部分的第一次金属化和官能化，并且突出了在吡啶环的周边位置C 5上的区域选择性金属化。

  DOI：

  10.1016/j.tet.2004.02.040
• 作为产物：
  描述：

  二氧化碳 、 N-(吡啶-4-基)三甲基乙酰胺 在 正丁基锂 、 四甲基乙二胺 作用下， 以 乙醚 、 正己烷 为溶剂， 以95%的产率得到4-新戊酰基氨基烟酸
  参考文献：
  名称：

  邻取代的氨基吡啶的合成。新戊酰氨基衍生物的金属化

  摘要：

  将三种异构体新戊酰氨基吡啶以超过80％的产率进行锂化。在乙醚中，在-10°下用2.5-3当量的复合BuLi-TMEDA处理氨基吡啶衍生物。锂化物种与各种亲电试剂的反应以良好的产率提供了许多邻位取代的新戊酰氨基吡啶。仲吡啶醇被氧化成相应的氨基吡啶基酮。已合成了吡啶并嘧啶，苯并萘啶以及天然抗肿瘤生物碱玫瑰树碱的类似物，显示了该方法的多功能性。

  DOI：

  10.1002/jhet.5570260119

文献信息

• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DERIVES DE BENZIMIDAZOLES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR VANILLOIDE
  申请人：AMGEN INC

  公开号：WO2004035549A1

  公开（公告）日：2004-04-29

  Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

  式（I）的化合物在治疗辣椒素受体介导的疾病方面很有用，如炎症性或神经病痛以及涉及感觉神经功能的疾病，如哮喘、类风湿性关节炎、骨关节炎、炎症性肠道疾病、尿失禁、偏头痛和牛皮癣。
• ESTEL, L.;LINARD, F.;MARSAIS, F.;GODARD, A.;QUEGUINER, G., J. HETEROCYCL. CHEM., 26,(1989) N, C. 105-112
  作者：ESTEL, L.、LINARD, F.、MARSAIS, F.、GODARD, A.、QUEGUINER, G.

  DOI：——

  日期：——
• First functionalization by metallation of the pyridine moiety of pyridopyrimidin-4(3H)-ones. Diazines. Part 36
  作者：Jérôme Audoux、Nelly Plé、Alain Turck、Guy Quéguiner

  DOI：10.1016/j.tet.2004.02.040

  日期：2004.4

  o-aminopyridine carboxylic acids, a general synthetic route leading to various pyridopyrimidin-4(3H)-ones is described. The first metallation and functionalization of the pyridine moiety has been studied and a regioselective metallation at the peri-position C5 of the pyridine ring has been highlighted.

  从邻氨基吡啶羧酸开始，描述了导致各种吡啶并嘧啶-4（3H）-一个的一般合成路线。已经研究了吡啶部分的第一次金属化和官能化，并且突出了在吡啶环的周边位置C 5上的区域选择性金属化。
• Synthesis of<i>ortho</i>-substituted aminopyridines. Metalation of pivaloylamino derivatives
  作者：L. Estel、F. Linard、F. Marsais、A. Godard、G. Quéguiner

  DOI：10.1002/jhet.5570260119

  日期：1989.1

  The three isomeric pivaloylaminopyridines were lithiated in more than 80% yields. Aminopyridine derivatives were treated by 2.5-3 equivalents of the complex BuLi-TMEDA at −10° in diethyl ether. Reaction of the lithiated species with various electrophiles afforded a number of ortho-substituted pivaloylaminopyridines in good yields. Secondary pyridine alcohols were oxidized to the corresponding aminopyridyl

  将三种异构体新戊酰氨基吡啶以超过80％的产率进行锂化。在乙醚中，在-10°下用2.5-3当量的复合BuLi-TMEDA处理氨基吡啶衍生物。锂化物种与各种亲电试剂的反应以良好的产率提供了许多邻位取代的新戊酰氨基吡啶。仲吡啶醇被氧化成相应的氨基吡啶基酮。已合成了吡啶并嘧啶，苯并萘啶以及天然抗肿瘤生物碱玫瑰树碱的类似物，显示了该方法的多功能性。